Skip to content
AnalystLens

Exelixis 8-K Report, Financial Results (Oct 29, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 29, 2024
Period End
October 29, 2024
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Dec ’19Dec ’19
  3. Leadership change8-K · May ’22May ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 8-K filed October 29, 2024. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. furnished a press release under Item 2.02 reporting its results for the quarter ended September 27, 2024 (presented as September 30, 2024) and providing a corporate update.

Total revenues were $539.5 milliona, including net product revenues of $478.1 million, compared with $471.9 million total revenues in the prior-year period. GAAP net income was $118.0 million, or $0.40 per diluted share, versus $1.0 million in the prior-year quarter. Non-GAAP net income was $135.7 million, or $0.47 per diluted share.

The quarter included a $51.7 millionb non-cash impairment charge on leased facilities not in use, and research and development expenses fell to $222.6 million from $332.6 million. The company raised its 2024 guidance. Total revenues are now expected at $2.150 billion to $2.200 billion (previously $1.975 billion to $2.075 billion), and net product revenues at $1.775 billion to $1.825 billion (previously $1.650 billion to $1.750 billion).

The filing also reports a favorable October 2024 District Court ruling rejecting MSN's challenge to three cabozantinib patents, which expire January 15, 2030, and a new Merck collaboration to evaluate zanzalintinib with KEYTRUDA in head and neck cancer and with WELIREG in renal cell carcinoma. Exelixis has repurchased $12.4 millionc of stock under a $500 million program authorized through the end of 2025.

Pipeline and regulatory milestones include an FDA sNDA for cabozantinib in advanced neuroendocrine tumors with a PDUFA target action date of April 3, 2025, a planned sNDA for cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer in the fourth quarter of 2024, and preliminary STELLAR-303 results expected in 2025. Ipsen submitted a European extension of indication application for CABOMETYX in neuroendocrine tumors.

Key Highlights

  1. Total revenues of $539.5 million for the quarter, up from $471.9 million, with net product revenues of $478.1 million.
  2. GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.47, versus $0.00 GAAP and $0.10 non-GAAP in the prior-year quarter.
  3. 2024 total revenue guidance raised to $2.150–$2.200 billion from $1.975–$2.075 billion; net product revenue guidance raised to $1.775–$1.825 billion.
  4. Favorable District Court ruling against MSN on three cabozantinib patents; generic entry date may be no earlier than January 15, 2030, subject to appeal.
  5. New Merck collaboration to evaluate zanzalintinib with KEYTRUDA in head and neck cancer and with WELIREG in renal cell carcinoma; Merck funds one phase 3 study.
  6. $51.7 million non-cash impairment charge on leased facilities not in use; R&D expenses decreased to $222.6 million from $332.6 million.
  7. FDA sNDA for cabozantinib in advanced neuroendocrine tumors accepted with a PDUFA target action date of April 3, 2025.

Frequently Asked Questions

  1. Why did Exelixis raise its 2024 revenue guidance?

    The filing says the increase reflects strong commercial performance of the cabozantinib franchise in the third quarter, along with the favorable patent ruling and the zanzalintinib collaboration with Merck, which management says generated momentum for future growth.

  2. What drove the difference between GAAP and non-GAAP net income?

    Non-GAAP net income excludes stock-based compensation expense, adjusted for the related tax effect. In the quarter, stock-based compensation totaled $23.0 million before tax ($8.8 million in R&D and $14.3 million in SG&A), and the tax effect was $5.3 million.

  3. What is the status of generic competition for CABOMETYX?

    The District Court ruled in Exelixis' favor against MSN's proposed generic and entered final judgment on October 23, 2024. Any FDA approval and U.S. launch of MSN's product may not occur before January 15, 2030, subject to Exelixis' potential additional regulatory exclusivity and possible appeal by either party. The FDA has not yet granted tentative approval, to the company's knowledge.

  4. What regulatory milestones are upcoming?

    The FDA accepted an sNDA for cabozantinib in previously treated advanced pNET and epNET with a PDUFA target date of April 3, 2025. Exelixis plans to submit an sNDA for cabozantinib with atezolizumab in mCRPC in the fourth quarter of 2024, and Ipsen has submitted an extension of indication application to the EMA for advanced NET.

  5. How much has Exelixis returned to shareholders through buybacks?

    The Board authorized up to $500 million of share repurchases through the end of 2025. As of September 30, 2024, Exelixis had repurchased $12.4 million of common stock at an average price of $25.61 per share.